Login to Your Account



Analysts: Dendreon's Future Solid

Prostate Cancer Takes Hit with Pfizer, AstraZeneca Failures

By Donna Young


Wednesday, September 29, 2010
The prostate cancer therapy arena was dealt two blows this week, with Pfizer Inc.'s Sutent (sunitinib malate) and AstraZeneca plc's zibotentan both failing to demonstrate an improvement in overall survival. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription